Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Should levodopa be used anymore?

Diederik Zegers de Beyl1

  • 1Service de Neurologie, Hôpital Erasme, U.L.B., Bruxelles, Belgium. diederik.zegers.de.beyl@ulb.ac.be

Acta Neurologica Belgica
|January 22, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intestinal levodopa infusion: the Belgian experience.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2014
Same author

Neuromuscular junction border conflict.

Journal of neurology·2010
Same author

Neck movement speed in cervical dystonia.

Movement disorders : official journal of the Movement Disorder Society·2009
Same author

SSEPs and prognosis in postanoxic coma: only short or also long latency responses?

Neurology·2007
Same author

Clinical and goniometric evaluation of patients with spasmodic torticollis.

Clinical biomechanics (Bristol, Avon)·2006
Same author

European consensus statement on the use of botulinum toxin type A in the management of adult spasticity.

Acta neurologica Belgica·2003
Same journal

Synergistic pain relief in cervical radiculopathy: A randomized trial of topical methylcobalamin gel with phonophoresis and Mulligan mobilization.

Acta neurologica Belgica·2026
Same journal

Characterizing cranial tremors in a case of spinocerebellar ataxia type 12: a unique positional tremor.

Acta neurologica Belgica·2026
Same journal

A case of coexistence of spinal intradural capillary hemangioma and craniocervical junction dural arteriovenous fistula.

Acta neurologica Belgica·2026
Same journal

Comment on "Content quality and reliability of youtube exercise videos for parkinson's disease".

Acta neurologica Belgica·2026
Same journal

A novel CHMP2B variant of uncertain significance in a patient with apathy, hyperorality, and mild language impairment.

Acta neurologica Belgica·2026
Same journal

Photon-counting CT-angiography in comparison to digital subtraction angiography and MR-angiography for assessing intra-aneurysmal flow disrupting devices.

Acta neurologica Belgica·2026
See all related articles

Levodopa is the most effective Parkinson's disease treatment, but can cause motor complications. Combining levodopa with dopamine agonists early may help manage these side effects, though current data are inconclusive.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Levodopa is a potent oral dopaminergic drug for Parkinson's disease (PD).
  • Chronic levodopa use often leads to difficult-to-manage dyskinesia and motor fluctuations in PD patients.
  • Dopamine agonists were investigated as a strategy to mitigate these side effects.

Purpose of the Study:

  • To evaluate if dopamine agonists can reduce levodopa-induced side effects in Parkinson's disease.
  • To assess the efficacy of combining levodopa with dopamine agonists compared to levodopa alone.

Main Methods:

  • Review of prospective clinical data on Parkinson's disease treatment regimens.
  • Analysis of treatment outcomes including efficacy and side effect profiles.

Main Results:

Related Experiment Videos

  • Current dopamine agonists have not effectively diminished levodopa-induced side effects.
  • Levodopa remains the most efficacious treatment for Parkinson's disease symptoms.
  • Prospective clinical data do not fully support the initial hypothesis.

Conclusions:

  • Levodopa is the cornerstone of Parkinson's disease management.
  • Clinicians often consider early combination therapy with levodopa and a dopamine agonist.
  • Further research is needed to optimize combination strategies for managing motor complications.